Cargando…
Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions
Background: Eukaryotic elongation factor 2 kinase (eEF2K) regulates the elongation stage of protein synthesis by phosphorylating eEF2, a process related to various diseases including cancer and cardiovascular and neurodegenerative diseases. In this study, we describe the identification of novel eEF2...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161098/ https://www.ncbi.nlm.nih.gov/pubmed/34065377 http://dx.doi.org/10.3390/medicines8050023 |
_version_ | 1783700433210966016 |
---|---|
author | Yoshimori, Atsushi Kawasaki, Enzo Murakami, Ryuta Kanai, Chisato |
author_facet | Yoshimori, Atsushi Kawasaki, Enzo Murakami, Ryuta Kanai, Chisato |
author_sort | Yoshimori, Atsushi |
collection | PubMed |
description | Background: Eukaryotic elongation factor 2 kinase (eEF2K) regulates the elongation stage of protein synthesis by phosphorylating eEF2, a process related to various diseases including cancer and cardiovascular and neurodegenerative diseases. In this study, we describe the identification of novel eEF2K inhibitors using high-throughput screening fingerprints (HTSFP) generated from predicted profiling of compound-protein interactions (CPIs). Methods: We utilized computationally generated HTSFPs referred to as chemical genomics-based fingerprint (CGBFP). Generally, HTSFPs are generated from multiple biochemical or cell-based assay data. On the other hand, CGBFPs are generated from computational prediction of CPIs using the Chemical Genomics-Based Virtual Screening (CGBVS) method. Therefore, CGBFPs do not have missing information mainly caused by the absence of assay data. Results: Chemogenomics-Based Similarity Profiling (CGBSP) of the screening library (2.6 million compounds) yielded 27 compounds which were evaluated for in vitro eEF2K inhibitory activity. Three compounds with interesting results were identified. Compounds 2 (IC [Formula: see text] = 11.05 μM) and 4 (IC [Formula: see text] = 43.54 μM) are thieno[2,3-b]pyridine derivatives that have the same scaffolds with a known eEF2K inhibitor, while compound 13 (IC [Formula: see text] = 70.13 μM) was a new thiophene-2-amine-type eEF2K inhibitor. Conclusions: CGBSP supplied an efficient strategy in the identification of novel eEF2K inhibitors and provided useful scaffolds for optimization. |
format | Online Article Text |
id | pubmed-8161098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81610982021-05-29 Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions Yoshimori, Atsushi Kawasaki, Enzo Murakami, Ryuta Kanai, Chisato Medicines (Basel) Article Background: Eukaryotic elongation factor 2 kinase (eEF2K) regulates the elongation stage of protein synthesis by phosphorylating eEF2, a process related to various diseases including cancer and cardiovascular and neurodegenerative diseases. In this study, we describe the identification of novel eEF2K inhibitors using high-throughput screening fingerprints (HTSFP) generated from predicted profiling of compound-protein interactions (CPIs). Methods: We utilized computationally generated HTSFPs referred to as chemical genomics-based fingerprint (CGBFP). Generally, HTSFPs are generated from multiple biochemical or cell-based assay data. On the other hand, CGBFPs are generated from computational prediction of CPIs using the Chemical Genomics-Based Virtual Screening (CGBVS) method. Therefore, CGBFPs do not have missing information mainly caused by the absence of assay data. Results: Chemogenomics-Based Similarity Profiling (CGBSP) of the screening library (2.6 million compounds) yielded 27 compounds which were evaluated for in vitro eEF2K inhibitory activity. Three compounds with interesting results were identified. Compounds 2 (IC [Formula: see text] = 11.05 μM) and 4 (IC [Formula: see text] = 43.54 μM) are thieno[2,3-b]pyridine derivatives that have the same scaffolds with a known eEF2K inhibitor, while compound 13 (IC [Formula: see text] = 70.13 μM) was a new thiophene-2-amine-type eEF2K inhibitor. Conclusions: CGBSP supplied an efficient strategy in the identification of novel eEF2K inhibitors and provided useful scaffolds for optimization. MDPI 2021-05-20 /pmc/articles/PMC8161098/ /pubmed/34065377 http://dx.doi.org/10.3390/medicines8050023 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yoshimori, Atsushi Kawasaki, Enzo Murakami, Ryuta Kanai, Chisato Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions |
title | Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions |
title_full | Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions |
title_fullStr | Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions |
title_full_unstemmed | Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions |
title_short | Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions |
title_sort | discovery of novel eef2k inhibitors using hts fingerprint generated from predicted profiling of compound-protein interactions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161098/ https://www.ncbi.nlm.nih.gov/pubmed/34065377 http://dx.doi.org/10.3390/medicines8050023 |
work_keys_str_mv | AT yoshimoriatsushi discoveryofnoveleef2kinhibitorsusinghtsfingerprintgeneratedfrompredictedprofilingofcompoundproteininteractions AT kawasakienzo discoveryofnoveleef2kinhibitorsusinghtsfingerprintgeneratedfrompredictedprofilingofcompoundproteininteractions AT murakamiryuta discoveryofnoveleef2kinhibitorsusinghtsfingerprintgeneratedfrompredictedprofilingofcompoundproteininteractions AT kanaichisato discoveryofnoveleef2kinhibitorsusinghtsfingerprintgeneratedfrompredictedprofilingofcompoundproteininteractions |